Yahoo Finance How to Find Strong Buy Medical Stocks Using the Zacks Rank
Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor.
Should You Buy #1 (Strong Buy)-Ranked DaVita HealthCare (DVA) for Your Portfolio?
DaVita HealthCare was upgraded to the Zacks Rank #1 list on September 10, 2024. The Zacks Rank is a unique stock-rating model that helps you take advantage of earnings estimate revision trends and provides a way to get into stocks highly sought after by institutional investors.
Denver, CO-headquartered DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
For fiscal 2024, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.37 to $9.99 per share. DVA boasts an average earnings surprise of 24.2%.
Earnings are forecasted to see growth of 18% for the current fiscal year, and sales are expected to increase 5.4%.
DVA has been moving higher over the past four weeks as well, up 8.6% compared to the S&P 500's gain of 1.5%.
Bottom Line
With a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, DaVita HealthCare could be just the stock to help your portfolio generate returns that could fund your retirement, your kids' college tuition, or your short- and long-term savings goals.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
